Abbott Laboratories
ABT
$126.34
-$0.44-0.35%
| Weiss Ratings | ABT - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Good | |||
| Risk Index | Fair | |||
| Risk Grade | C | |||
| Reward Grade | B+ | |||
| Rating Factors | ABT - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Fair | |||
| Growth Index | Good | |||
| Efficiency Index | Excellent | |||
| Solvency Index | Excellent | |||
| Total Return Index | Fair | |||
| Volatility Index | Fair | |||
| Beta / Standard Deviation | ABT - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.34 | |||
| Price History | ABT - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -3.02% | |||
| 30-Day Total Return | -1.47% | |||
| 60-Day Total Return | 11.18% | |||
| 90-Day Total Return | 10.15% | |||
| Year to Date Total Return | 11.95% | |||
| 1-Year Total Return | 15.61% | |||
| 2-Year Total Return | 33.77% | |||
| 3-Year Total Return | 9.95% | |||
| 5-Year Total Return | 119.65% | |||
| 52-Week High % Change | -10.23% | |||
| 52-Week Low % Change | 27.15% | |||
| Price | ABT - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $141.23 | |||
| 52-Week Low Price | $99.71 | |||
| 52-Week Low Price (Date) | Jul 18, 2024 | |||
| 52-Week High Price (Date) | Mar 04, 2025 | |||
| Valuation | ABT - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 219.88B | |||
| Enterprise Value | 227.42B | |||
| Price/Earnings (TTM) | 16.59 | |||
| Earnings Per Share (TTM) | 7.64 | |||
| Earnings Per Share Growth | 134.55% | |||
| Price/Earnings To Growth | 0.12 | |||
| Price/Sales (TTM) | 5.28 | |||
| Price/Book (Q) | 4.61 | |||
| Enterprise Value/Revenue (TTM) | 5.42 | |||
| Price | $126.34 | |||
| Enterprise Value/EBITDA (TTM) | 21.23 | |||
| Enterprise Value/EBIT | 30.34 | |||
| Market Cap Category | Mega Cap | |||
| Dividends and Shares | ABT - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 1.75B | |||
| Dividend Yield | 1.77% | |||
| Div. Per Share (Most Recent) | $0.59 | |||
| Dividend Per Share (TTM) | $2.24 | |||
| Payout Ratio (TTM) | 28.62% | |||
| Dividend Per Share (Most Recent) | $0.59 | |||
| Company Info | ABT - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 224 667 6100 | |||
| Address | 100 Abbott Park Road North Chicago, IL 60064-6400 | |||
| Website | www.abbott.com | |||
| Country | United States | |||
| Year Founded | 1888 | |||
| Profitability | ABT - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 17.86% | |||
| Profit Margin | 31.94% | |||
| Management Effectiveness | ABT - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 6.06% | |||
| Return on Equity | 30.91% | |||
| Income Statement | ABT - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 41.95B | |||
| Total Revenue (TTM) | 41.95B | |||
| Revenue Per Share | $24.03 | |||
| Gross Profit (TTM) | 23.31B | |||
| EBITDA (TTM) | 10.71B | |||
| EBIT (TTM) | 7.50B | |||
| Net Income (TTM) | 13.40B | |||
| Net Income Avl. to Common (TTM) | 13.40B | |||
| Total Revenue Growth (Q YOY) | 7.16% | |||
| Earnings Growth (Q YOY) | 478.98% | |||
| EPS Diluted (TTM) | 7.64 | |||
| EPS Diluted Growth (Q YOY) | 479.43% | |||
| Balance Sheet | ABT - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 7.97B | |||
| Cash Per Share (Q) | $4.56 | |||
| Total Current Assets (Q) | 23.66B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 47.90B | |||
| Current Ratio (Q) | 1.671 | |||
| Book Value Per Share (Q) | $27.52 | |||
| Total Assets (Q) | 81.41B | |||
| Total Current Liabilities (Q) | 14.16B | |||
| Total Debt (Q) | 15.28B | |||
| Total Liabilities (Q) | 33.51B | |||
| Total Common Equity (Q) | 47.66B | |||
| Cash Flow | ABT - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -2.34B | |||
| Cash from Financing (TTM) | -5.40B | |||
| Net Change in Cash (TTM) | 720.00M | |||
| Levered Free Cash Flow (TTM) | 5.61B | |||
| Cash from Operations (TTM) | 8.56B | |||
